Belite Bio to Participate in the 2025 Maxim Growth Summit
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE) announced that its executive management team will participate in the Maxim Growth Summit on October 22, 2025.
Belite is a clinical-stage company developing novel therapeutics for degenerative retinal diseases. Investors or partners seeking a one-on-one meeting are instructed to contact their Maxim representative to schedule.
Positive
- None.
Negative
- None.
News Market Reaction 21 Alerts
On the day this news was published, BLTE gained 9.61%, reflecting a notable positive market reaction. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $259M to the company's valuation, bringing the market cap to $2.96B at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will be participating in the Maxim Growth Summit on October 22, 2025.
To schedule a one-on-one meeting with management, please reach out to your Maxim representative.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as STGD1 and GA in advanced dry AMD, in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When will Belite Bio (NASDAQ: BLTE) participate in the Maxim Growth Summit?
How can investors schedule a one-on-one meeting with Belite Bio management at the Maxim Growth Summit?
What will Belite Bio discuss at the October 22, 2025 Maxim Growth Summit?
What is Belite Bio's (BLTE) clinical focus mentioned for the Maxim Growth Summit?
Will Belite Bio provide a public webcast or investor presentation at the Maxim Growth Summit?
Who should I contact to arrange meetings with Belite Bio management at the Maxim Growth Summit?
